TLR7 and infection: We considered the case of Menveo (GSK), a quadrivalent glycoconjugate meningococcal vaccine consisting of the four serogroups A, C, W135, and Y, which is able to stimulate a protective immune response against infection from all these bacterial strains, and evaluated the capacity of Alum-TLR7 to enhance the immune response versus all components and in particular to the A antigenic component (MenA) whose immunogenicity is partly reduced when combined with the C, W135 and Y antigenic components in the mouse animal model.